Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis.

Spellberg B, Andes D, Perez M, Anglim A, Bonilla H, Mathisen GE, Walsh TJ, Ibrahim AS.

Antimicrob Agents Chemother. 2009 Jul;53(7):3122-5. doi: 10.1128/AAC.00361-09. Epub 2009 May 11.

2.

Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.

Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H.

Ann Hematol. 2013 Jan;92(2):191-8. doi: 10.1007/s00277-012-1594-z. Epub 2012 Oct 17.

PMID:
23073603
3.

Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.

Cappellini MD, Bejaoui M, Agaoglu L, Canatan D, Capra M, Cohen A, Drelichman G, Economou M, Fattoum S, Kattamis A, Kilinc Y, Perrotta S, Piga A, Porter JB, Griffel L, Dong V, Clark J, Aydinok Y.

Blood. 2011 Jul 28;118(4):884-93. doi: 10.1182/blood-2010-11-316646. Epub 2011 May 31. Erratum in: Blood. 2011 Nov 3;118(18):5060.

4.

Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).

Angelucci E, Santini V, Di Tucci AA, Quaresmini G, Finelli C, Volpe A, Quarta G, Rivellini F, Sanpaolo G, Cilloni D, Salvi F, Caocci G, Molteni A, Vallisa D, Voso MT, Fenu S, Borin L, Latte G, Alimena G, Storti S, Piciocchi A, Fazi P, Vignetti M, Tura S.

Eur J Haematol. 2014 Jun;92(6):527-36. doi: 10.1111/ejh.12300. Epub 2014 Apr 10.

PMID:
24580147
5.

A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.

Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, Files B, Hassell K, Kelly P, Wilson F, Bernaudin F, Forni GL, Okpala I, Ressayre-Djaffer C, Alberti D, Holland J, Marks P, Fung E, Fischer R, Mueller BU, Coates T; Deferasirox in Sickle Cell Investigators.

Br J Haematol. 2007 Feb;136(3):501-8.

6.

Deferasirox for managing transfusional iron overload in people with sickle cell disease.

Meerpohl JJ, Antes G, Rücker G, Fleeman N, Niemeyer C, Bassler D.

Cochrane Database Syst Rev. 2010 Aug 4;(8):CD007477. doi: 10.1002/14651858.CD007477.pub2. Review.

PMID:
20687088
7.

Safety and efficacy of deferasirox in multitransfused Indian children with β-thalassaemia major.

Chandra J, Chaudhary H, Pemde H, Singh V, Dutta AK.

Ann Trop Paediatr. 2011;31(1):47-51. doi: 10.1179/1465328110Y.0000000002.

PMID:
21262109
8.

The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.

Totadri S, Bansal D, Bhatia P, Attri SV, Trehan A, Marwaha RK.

Pediatr Blood Cancer. 2015 Sep;62(9):1592-6. doi: 10.1002/pbc.25533. Epub 2015 Mar 28.

PMID:
25820920
9.

Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine.

Pennell DJ, Porter JB, Piga A, Lai YR, El-Beshlawy A, Elalfy M, Yesilipek A, Kilinç Y, Habr D, Musallam KM, Shen J, Aydinok Y; CORDELIA study investigators.

Am J Hematol. 2015 Feb;90(2):91-6. doi: 10.1002/ajh.23876. Epub 2014 Nov 19.

10.

Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.

Vichinsky E, Torres M, Minniti CP, Barrette S, Habr D, Zhang Y, Files B; study CICL670A2201 investigators.

Am J Hematol. 2013 Dec;88(12):1068-73. doi: 10.1002/ajh.23569. Epub 2013 Sep 19.

11.
12.

Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease.

Vichinsky E, Bernaudin F, Forni GL, Gardner R, Hassell K, Heeney MM, Inusa B, Kutlar A, Lane P, Mathias L, Porter J, Tebbi C, Wilson F, Griffel L, Deng W, Giannone V, Coates T.

Br J Haematol. 2011 Aug;154(3):387-97. doi: 10.1111/j.1365-2141.2011.08720.x. Epub 2011 May 19.

13.

Proximal muscular atrophy and weakness: An unusual adverse effect of deferasirox iron chelation therapy.

Vill K, Müller-Felber W, Teusch V, Blaschek A, Gerstl L, Huetker S, Albert MH.

Neuromuscul Disord. 2016 Apr-May;26(4-5):322-5. doi: 10.1016/j.nmd.2016.02.011. Epub 2016 Feb 23.

PMID:
27068298
14.

Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload.

Chen CH, Shu KH, Yang Y.

Hematology. 2015 Jun;20(5):304-10. doi: 10.1179/1607845414Y.0000000199. Epub 2014 Sep 9.

PMID:
25200910
15.

The iron chelator deferasirox protects mice from mucormycosis through iron starvation.

Ibrahim AS, Gebermariam T, Fu Y, Lin L, Husseiny MI, French SW, Schwartz J, Skory CD, Edwards JE Jr, Spellberg BJ.

J Clin Invest. 2007 Sep;117(9):2649-57.

16.

Iron chelation therapy of transfusion-dependent β-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic?

Diamantidis MD, Neokleous N, Agapidou A, Vetsiou E, Manafas A, Fotiou P, Vlachaki E.

Int J Hematol. 2016 May;103(5):537-44. doi: 10.1007/s12185-016-1945-y. Epub 2016 Feb 9.

PMID:
26861970
18.

Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.

Porter JB, Elalfy MS, Taher AT, Aydinok Y, Chan LL, Lee SH, Sutcharitchan P, Habr D, Martin N, El-Beshlawy A.

Ann Hematol. 2013 Jan;92(2):211-9. doi: 10.1007/s00277-012-1588-x. Epub 2012 Oct 21.

19.

Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation.

Vallejo C, Batlle M, Vázquez L, Solano C, Sampol A, Duarte R, Hernández D, López J, Rovira M, Jiménez S, Valcárcel D, Belloch V, Jiménez M, Jarque I; Subcommittee of Non-Infectious Complications of the Grupo Español de Trasplante Hematopoyético (GETH).

Haematologica. 2014 Oct;99(10):1632-7. doi: 10.3324/haematol.2014.105908. Epub 2014 Jul 4.

20.

The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial.

Spellberg B, Ibrahim AS, Chin-Hong PV, Kontoyiannis DP, Morris MI, Perfect JR, Fredricks D, Brass EP.

J Antimicrob Chemother. 2012 Mar;67(3):715-22. doi: 10.1093/jac/dkr375. Epub 2011 Sep 20.

Supplemental Content

Support Center